Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 75

1.

Antiphospholipid syndrome and direct oral anticoagulants: to the future and back again?

Wahl D.

Br J Haematol. 2020 Jan 21. doi: 10.1111/bjh.16369. [Epub ahead of print] No abstract available.

PMID:
31960410
2.

Detection of anti-domain I antibodies by chemiluminescence enables the identification of high-risk antiphospholipid syndrome patients: a multicenter multiplatform study.

Yin D, Chayoua W, Kelchtermans H, de Groot PG, Moore GW, Gris JC, Zuily S, Musial J, de Laat B, Devreese KMJ.

J Thromb Haemost. 2019 Nov 21. doi: 10.1111/jth.14682. [Epub ahead of print]

PMID:
31749277
3.

Association of antiphospholipid antibodies with active digital ulceration in systemic sclerosis.

Martin M, Martinez C, Arnaud L, Weber JC, Poindron V, Blaison G, Kieffer P, Bonnotte B, Berthier S, Wahl D, Maurier F, Pennaforte JL, Bielefeld P, Magy-Bertrand N, Devilliers H, Martin T.

RMD Open. 2019 Sep 20;5(2):e001012. doi: 10.1136/rmdopen-2019-001012. eCollection 2019. No abstract available.

4.

Impact of antiphospholipid syndrome iBook on medical students' improvement of knowledge: An international randomized controlled study.

Zuily S, Phialy L, Sevim E, Germain E, Unlu O, Dufrost V, Risse J, Clerc-Urmès I, Baumann C, Berman JR, Lockshin MD, Wahl D, Erkan D.

Eur J Rheumatol. 2019 Sep 5;6(4):207-211. doi: 10.5152/eurjrheum.2019.19030.

5.

Disease-specific quality of life following a flare in systemic lupus erythematosus: an item response theory analysis of the French EQUAL cohort.

Corneloup M, Maurier F, Wahl D, Muller G, Aumaitre O, Seve P, Blaison G, Pennaforte JL, Martin T, Magy-Bertrand N, Berthier S, Arnaud L, Bourredjem A, Amoura Z, Devilliers H.

Rheumatology (Oxford). 2019 Oct 17. pii: kez451. doi: 10.1093/rheumatology/kez451. [Epub ahead of print]

PMID:
31620787
6.

Direct Oral Anticoagulants in Antiphospholipid Syndrome: Too Early or Too Late?

Wahl D, Dufrost V.

Ann Intern Med. 2019 Oct 15. doi: 10.7326/M19-2815. [Epub ahead of print] No abstract available.

PMID:
31610546
7.

Extended persistence of antiphospholipid antibodies beyond the 12-week time interval: Association with baseline antiphospholipid antibodies titres.

Devignes J, Smaïl-Tabbone M, Hervé A, Cagninacci G, Devignes MD, Lecompte T, Zuily S, Wahl D.

Int J Lab Hematol. 2019 Dec;41(6):726-730. doi: 10.1111/ijlh.13094. Epub 2019 Sep 15.

PMID:
31523903
8.

Antiphospholipid antibodies and the risk of thrombocytopenia in patients with systemic lupus erythematosus: A systematic review and meta-analysis.

Chock YP, Moulinet T, Dufrost V, Erkan D, Wahl D, Zuily S.

Autoimmun Rev. 2019 Nov;18(11):102395. doi: 10.1016/j.autrev.2019.102395. Epub 2019 Sep 11.

PMID:
31520800
9.

The (non-)sense of detecting anti-cardiolipin and anti-β2glycoprotein I IgM antibodies in the antiphospholipid syndrome.

Chayoua W, Kelchtermans H, Gris JC, Moore GW, Musiał J, Wahl D, de Groot PG, de Laat B, Devreese KMJ.

J Thromb Haemost. 2020 Jan;18(1):169-179. doi: 10.1111/jth.14633. Epub 2019 Sep 27.

PMID:
31519058
10.

EULAR recommendations for the management of antiphospholipid syndrome in adults.

Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, Cuadrado MJ, Dörner T, Ferrer-Oliveras R, Hambly K, Khamashta MA, King J, Marchiori F, Meroni PL, Mosca M, Pengo V, Raio L, Ruiz-Irastorza G, Shoenfeld Y, Stojanovich L, Svenungsson E, Wahl D, Tincani A, Ward MM.

Ann Rheum Dis. 2019 Oct;78(10):1296-1304. doi: 10.1136/annrheumdis-2019-215213. Epub 2019 May 15.

PMID:
31092409
11.

Detection of Anti-Cardiolipin and Anti-β2glycoprotein I Antibodies Differs between Platforms without Influence on Association with Clinical Symptoms.

Chayoua W, Kelchtermans H, Moore GW, Gris JC, Musial J, Wahl D, Zuily S, Gianniello F, Fontana P, Remijn J, Urbanus RT, de Laat B, Devreese KMJ.

Thromb Haemost. 2019 May;119(5):797-806. doi: 10.1055/s-0039-1679901. Epub 2019 Mar 1.

PMID:
30822809
12.

Brief Report on the 11th Meeting of the European Forum on Antiphospholipid Antibodies.

Chayouâ W, Yin D, de Groot PG, Zuily S, Wahl D, de Laat B, Kelchtermans H.

Curr Rheumatol Rep. 2019 Feb 11;21(2):6. doi: 10.1007/s11926-019-0805-1. Review. No abstract available.

13.

Heart valve involvement in antiphospholipid syndrome: More than you think!

Zuily S.

Int J Cardiol. 2019 Jun 1;284:96-97. doi: 10.1016/j.ijcard.2018.10.021. Epub 2018 Oct 6. No abstract available.

PMID:
30301564
14.

Brief Report on the 10th Meeting of the European Forum on Antiphospholipid Antibodies.

Eschwège V, Yelnik CM, Zuily S, Wahl D.

Curr Rheumatol Rep. 2018 Aug 21;20(10):63. doi: 10.1007/s11926-018-0767-8. No abstract available.

PMID:
30128935
15.

Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis.

Dufrost V, Risse J, Reshetnyak T, Satybaldyeva M, Du Y, Yan XX, Salta S, Gerotziafas G, Jing ZC, Elalamy I, Wahl D, Zuily S.

Autoimmun Rev. 2018 Oct;17(10):1011-1021. doi: 10.1016/j.autrev.2018.04.009. Epub 2018 Aug 11. Review.

PMID:
30103045
16.

Identification of high thrombotic risk triple-positive antiphospholipid syndrome patients is dependent on anti-cardiolipin and anti-β2glycoprotein I antibody detection assays.

Chayoua W, Kelchtermans H, Moore GW, Musiał J, Wahl D, de Laat B, Devreese KMJ.

J Thromb Haemost. 2018 Oct;16(10):2016-2023. doi: 10.1111/jth.14261. Epub 2018 Aug 24.

PMID:
30079628
17.

Prothrombin conversion is accelerated in the antiphospholipid syndrome and insensitive to thrombomodulin.

Kremers RMW, Zuily S, Kelchtermans H, Peters TC, Bloemen S, Regnault V, Hemker HC, de Groot PG, Wahl D, de Laat B.

Blood Adv. 2018 Jun 12;2(11):1315-1324. doi: 10.1182/bloodadvances.2018018036.

18.

"Antiphospholipids": the more, the worse?

Wahl D.

Blood. 2018 May 10;131(19):2092-2094. doi: 10.1182/blood-2018-03-837831. No abstract available.

PMID:
29748169
19.

The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository.

Unlu O, Erkan D, Barbhaiya M, Andrade D, Nascimento I, Rosa R, Banzato A, Pengo V, Ugarte A, Gerosa M, Ji L, Efthymiou M, Branch DW, de Jesus GR, Tincani A, Belmont HM, Fortin PR, Petri M, Rodriguez E, Pons-Estel GJ, Knight JS, Atsumi T, Willis R, Zuily S, Tektonidou MG; AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking Investigators.

Arthritis Care Res (Hoboken). 2019 Jan;71(1):134-141. doi: 10.1002/acr.23584.

20.

Comment on: Failure of rivaroxaban to prevent thrombosis in four patients with anti-phospholipid syndrome: reply.

Dufrost V, Risse J, Wahl D, Zuily S.

Rheumatology (Oxford). 2018 May 1;57(5):939-940. doi: 10.1093/rheumatology/kex464. No abstract available.

PMID:
29373692

Supplemental Content

Loading ...
Support Center